SG39393G - Azabicyclononyl-indazole-carboxamide having 5-ht antagonist activity - Google Patents

Azabicyclononyl-indazole-carboxamide having 5-ht antagonist activity

Info

Publication number
SG39393G
SG39393G SG393/93A SG39393A SG39393G SG 39393 G SG39393 G SG 39393G SG 393/93 A SG393/93 A SG 393/93A SG 39393 A SG39393 A SG 39393A SG 39393 G SG39393 G SG 39393G
Authority
SG
Singapore
Prior art keywords
azabicyclononyl
indazole
carboxamide
antagonist activity
antagonist
Prior art date
Application number
SG393/93A
Other languages
English (en)
Original Assignee
Beecham Group Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26289173&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG39393(G) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB858510752A external-priority patent/GB8510752D0/en
Priority claimed from GB858525913A external-priority patent/GB8525913D0/en
Application filed by Beecham Group Plc filed Critical Beecham Group Plc
Publication of SG39393G publication Critical patent/SG39393G/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
    • C07D451/06—Oxygen atoms
    • C07D451/12—Oxygen atoms acylated by aromatic or heteroaromatic carboxylic acids, e.g. cocaine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/14—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing 9-azabicyclo [3.3.1] nonane ring systems, e.g. granatane, 2-aza-adamantane; Cyclic acetals thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/06—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing isoquinuclidine ring systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Anesthesiology (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
SG393/93A 1985-04-27 1993-04-07 Azabicyclononyl-indazole-carboxamide having 5-ht antagonist activity SG39393G (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB858510752A GB8510752D0 (en) 1985-04-27 1985-04-27 Compounds
GB858525913A GB8525913D0 (en) 1985-10-21 1985-10-21 Compounds

Publications (1)

Publication Number Publication Date
SG39393G true SG39393G (en) 1993-06-11

Family

ID=26289173

Family Applications (1)

Application Number Title Priority Date Filing Date
SG393/93A SG39393G (en) 1985-04-27 1993-04-07 Azabicyclononyl-indazole-carboxamide having 5-ht antagonist activity

Country Status (17)

Country Link
US (2) US4886808A (fr)
EP (2) EP0200444B1 (fr)
JP (1) JP2696457B2 (fr)
AU (1) AU594670B2 (fr)
BG (1) BG61324B2 (fr)
CA (1) CA1296004C (fr)
CY (1) CY1721A (fr)
CZ (1) CZ286325B6 (fr)
DE (2) DE3650772T2 (fr)
DK (1) DK170166B1 (fr)
ES (1) ES8707948A1 (fr)
GR (1) GR861103B (fr)
HK (1) HK66993A (fr)
IE (1) IE58313B1 (fr)
NZ (1) NZ215945A (fr)
PT (1) PT82463B (fr)
SG (1) SG39393G (fr)

Families Citing this family (111)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3650772T2 (de) * 1985-04-27 2003-04-03 F. Hoffmann-La Roche Ag, Basel Derivate von Indazole-3-carboxamide und -3-carboxylsäure
GB8623142D0 (en) * 1986-09-26 1986-10-29 Beecham Group Plc Compounds
US4937247A (en) * 1985-04-27 1990-06-26 Beecham Group P.L.C. 1-acyl indazoles
GB8515845D0 (en) * 1985-06-22 1985-07-24 Beecham Group Plc Treatment
GB8518658D0 (en) * 1985-07-24 1985-08-29 Glaxo Group Ltd Medicaments
US5204356A (en) * 1985-07-24 1993-04-20 Glaxo Group Limited Treatment of anxiety
DE3687980T2 (de) * 1986-01-07 1993-06-17 Beecham Group Plc Indolderivate mit einer azabicyclischen seitenkette, verfahren zu ihrer herstellung, zwischenprodukte und pharmazeutische zusammensetzungen.
DE3782107T2 (de) * 1986-07-25 1993-04-01 Beecham Group Plc Azabicyclische verbindungen, verfahren zu ihrer herstellung und ihre pharmazeutische verwendung.
HU895334D0 (en) * 1986-07-30 1990-01-28 Sandoz Ag Process for the preparation of nasal pharmaceutical compositions
AT396870B (de) * 1986-08-07 1993-12-27 Sandoz Ag Verfahren zur herstellung einer galenischen formulierung zur nasalen verabreichung von serotoninantagonisten
WO1988003801A1 (fr) * 1986-11-21 1988-06-02 Glaxo Group Limited Medicaments pour le traitement ou la prevention d'un syndrome de reaction a la privation
US5200414A (en) * 1986-12-17 1993-04-06 Glaxo Group Limited Methods for the treatment of cognitive disorders
DE3788057T2 (de) * 1986-12-17 1994-03-03 Glaxo Group Ltd Verwendung von heterocyclischen Verbindungen zur Behandlung von Depressionen.
EP0551963A3 (en) * 1986-12-17 1993-09-01 Glaxo Group Limited Use of heterocyclic derivatives for the manufacture of medicaments
US5190954A (en) * 1986-12-17 1993-03-02 Glaxo Group Limited Methods for the treatment of cognitive disorders
GB8806990D0 (en) * 1988-03-23 1988-04-27 Beecham Group Plc Novel compounds
GB8701022D0 (en) * 1987-01-19 1987-02-18 Beecham Group Plc Treatment
DE3852145T2 (de) * 1987-02-18 1995-04-06 Beecham Group Plc Indolderivate, Verfahren zu deren Herstellung und pharmazeutische Präparate, die diese enthalten.
DE3876006T2 (de) * 1987-04-14 1993-03-25 Glaxo Group Ltd Keton-derivate.
EP0289170B1 (fr) 1987-04-25 1993-06-23 Beecham Group Plc Composés azabicycliques, leur procédé de préparation et compositions pharmaceutiques les contenant
DE3822792C2 (de) * 1987-07-11 1997-11-27 Sandoz Ag Neue Verwendung von 5HT¶3¶-Antagonisten
GB8723157D0 (en) * 1987-10-02 1987-11-04 Beecham Group Plc Compounds
US5098909A (en) * 1987-11-14 1992-03-24 Beecham Group, P.L.C. 5-ht3 receptor antagonists for treatment of cough and bronchoconstriction
IE62231B1 (en) * 1987-12-24 1995-01-11 Wyeth John & Brother Ltd Heterocyclic compounds
EP0350130A3 (fr) * 1988-07-07 1991-07-10 Duphar International Research B.V 1H-indazoles 1,7-annelés substitués
US5166341A (en) * 1988-07-29 1992-11-24 Dainippon Pharmaceutical Co., Ltd. 6-amino-1,4-hexahydro-1H-diazepine derivatives
NZ230068A (en) * 1988-07-29 1991-07-26 Dainippon Pharmaceutical Co Indazole-3-carboxylic acid esters and amides of diaza compounds having 6,7, or 8 ring members: preparatory processes and pharmaceutical compositions
CA2004911A1 (fr) * 1988-12-22 1990-06-22 Mitsuaki Ohta Derives de 4,5,6,7-tetrahydrobenzimidazole
EP0381422B1 (fr) * 1989-02-02 1996-10-23 Yamanouchi Pharmaceutical Co. Ltd. Dérivés de tétrahydrobenzimidazole
GB8904551D0 (en) * 1989-02-28 1989-04-12 Glaxo Group Ltd Chemical compounds
GB8916682D0 (en) * 1989-07-21 1989-09-06 Beecham Group Plc Pharmaceutical compounds
US4992461A (en) * 1989-09-11 1991-02-12 G. D. Searle & Co. N-azabicyclo(3.3.0)octane amides of aromatic acids, compositions, and methods of use thereof
US5126343A (en) * 1989-09-11 1992-06-30 G. D. Searle & Co. N-azabicyclo [3.3.0]octane amides of aromatic acids
US5180728A (en) * 1989-09-25 1993-01-19 Fujisawa Pharmaceutical Company, Ltd. Pyrimidoindole derivatives and processes for preparation thereof
US5225419A (en) * 1989-10-14 1993-07-06 John Wyeth & Brother, Limited Certain 1,8-ethano or propano-1,4-dihydro-4-oxo-quinoline-3-carboxamides and derivatives thereof
GB2236751B (en) 1989-10-14 1993-04-28 Wyeth John & Brother Ltd Heterocyclic compounds
GB8923209D0 (en) * 1989-10-14 1989-11-29 Wyeth John & Brother Ltd Heterocyclic compounds
GB8928837D0 (en) * 1989-12-21 1990-02-28 Beecham Group Plc Pharmaceuticals
GB9009389D0 (en) * 1990-04-26 1990-06-20 Smith Kline French Lab Treatment
GB9009542D0 (en) * 1990-04-27 1990-06-20 Beecham Group Plc Novel compounds
AU7618991A (en) * 1990-05-14 1991-11-14 Syntex (U.S.A.) Inc. Novel tricyclic compounds
US5202318A (en) * 1990-05-14 1993-04-13 Syntex (U.S.A.) Inc. Tricyclic compounds acting at serotonin receptor subtypes
JP3122671B2 (ja) * 1990-05-23 2001-01-09 協和醗酵工業株式会社 複素環式化合物
GB9020927D0 (en) * 1990-09-26 1990-11-07 Beecham Group Plc Pharmaceuticals
US5200415A (en) * 1990-11-01 1993-04-06 Asahi Kasei Kogyo Kabushiki Kaisha Pyrazolo[1,5-a]pyridine-3-carboxylic acid derivatives and their pharmaceutical use
HU211081B (en) * 1990-12-18 1995-10-30 Sandoz Ag Process for producing indole derivatives as serotonin antagonists and pharmaceutical compositions containing the same
GB9101221D0 (en) * 1991-01-19 1991-02-27 Smithkline Beecham Plc Pharmaceuticals
US5929059A (en) * 1991-01-19 1999-07-27 Smithkline Beecham P.L.C. Pharmaceutical compositions containing granisetron and dexamethasone
US5143923B1 (en) * 1991-04-29 1993-11-02 Hoechst-Roussel Pharmaceuticals Incorporated Benzoisothiazole-and benzisoxazole-3-carboxamides
US5225412A (en) * 1991-04-29 1993-07-06 Hoechst-Roussel Pharmaceuticals Incorporated Benzoisothiazole-and benzisoxazole-3-carboxamides
US5955470A (en) * 1991-06-11 1999-09-21 Merrell Pharmaceuticals, Inc. Derivatives of amide analogs of certain methano bridged quinolizines
EP0517984A1 (fr) * 1991-06-11 1992-12-16 Merrell Dow Pharmaceuticals Inc. Derivés d'analogues d'amide de quinolizines à pont méthano
US5492919A (en) * 1991-08-03 1996-02-20 Smithkline Beecham P.L.C. 5-HT4 receptor antagonists
NZ243993A (en) * 1991-08-20 1994-10-26 Smithkline Beecham Plc Pharmaceutical compositions having 5-ht4 receptor antagonist activity and selected compounds having such activity
JPH0557982A (ja) * 1991-09-02 1993-03-09 Canon Inc キヤリツジ駆動方法
EP1082959A1 (fr) * 1991-09-20 2001-03-14 Glaxo Group Limited Utilisation des NK1-antagonistes pour le traitement de la depression
WO1993014745A1 (fr) * 1992-01-23 1993-08-05 Smithkline Beecham Plc Utilisation d'antagonistes de recepteur de 5-ht4 comme medicaments pour traiter la migraine
US5344831A (en) * 1992-01-31 1994-09-06 Nisshin Flour Milling Co., Ltd. Diazabicyclo derivatives
JP2699794B2 (ja) * 1992-03-12 1998-01-19 三菱化学株式会社 チエノ〔３，２−ｂ〕ピリジン誘導体
US5236931A (en) * 1992-03-26 1993-08-17 A. H. Robins Company, Incorporated 2-substituted benzamide and benzoate derivatives of 3-aminoquinuclidine and 3-quinuclidinol
GR1001378B (el) * 1992-10-08 1993-10-29 Smithkline Beecham Plc Ανταγωνιστές 5-ΗΤ4 πιπεριδυλαλκυλίου.
ES2056728B1 (es) * 1992-10-28 1995-05-01 Smithkline Beecham Plc Nuevos derivados de piperidilo y aminoalquilo con actividad antagonista del receptor 5-ht4
GB9305593D0 (en) * 1993-03-18 1993-05-05 Smithkline Beecham Plc Pharmaceuticals
CN1039623C (zh) * 1993-10-22 1998-09-02 中国人民解放军军事医学科学院毒物药物研究所 一种防治运动病综合征的药物组合物及其制备方法
GB9404055D0 (en) * 1994-03-03 1994-04-20 Smithkline Beecham Plc Novel process
GB9406857D0 (en) * 1994-04-07 1994-06-01 Sandoz Ltd Improvements in or relating to organic compounds
GB9412995D0 (en) * 1994-06-28 1994-10-26 Prendergast Kenneth F Safety enhancing pharmaceutical compositions of an active indazole
US5710323A (en) * 1994-09-29 1998-01-20 Idemitsu Petrochemical Co., Ltd. Process for producing monocarboxylic and/or dicarboxylic acids
GB9502583D0 (en) * 1995-02-10 1995-03-29 Smithkline Beecham Plc Novel process
GB9502582D0 (en) * 1995-02-10 1995-03-29 Smithkline Beecham Plc Novel process
GB9504078D0 (en) * 1995-03-01 1995-04-19 Smithkline Beecham Plc Novel process
ES2124162B1 (es) * 1995-03-01 1999-11-16 Smithkline Beecham Plc Un nuevo procedimiento para preparar compuestos farmaceuticamente activos.
GB9506119D0 (en) * 1995-03-25 1995-05-10 Smithkline Beecham Plc Chemical process
US5880121A (en) * 1996-01-05 1999-03-09 Hoechst Marion Roussel Inc. 4,5-dihydronaphth (1,2-c) isoxazoles and derivatives thereof
GB9602866D0 (en) 1996-02-13 1996-04-10 Smithkline Beecham Plc Novel process
GB9602862D0 (en) * 1996-02-13 1996-04-10 Smithkline Beecham Plc Novel process
US6294548B1 (en) * 1998-05-04 2001-09-25 Hoffmann-La Roche Inc. Multidose vial formulations for administering endo-N-(9-methyl-9-azabicyclo[3.3.1]non-3-yl)-1-methyl-1H-indazole-3-carboxamide hydrochloride
JP2000198734A (ja) * 1998-12-30 2000-07-18 Pfizer Inc 胃運動性減弱および関連疾患の治療のための運動性増強薬
KR20010112673A (ko) * 2000-06-09 2001-12-21 김환기 트로피세트론 염산염(일반식ⅰ)의 제조방법
ES2197001B1 (es) 2002-03-26 2004-11-16 Laboratorios Vita, S.A. Procedimiento de obtencion de un compuesto farmaceuticamente activo.
AU2003276919B2 (en) * 2002-09-25 2013-05-16 Memory Pharmaceuticals Corporation Indazoles, benzothiazoles, and benzoisothiazoles, and preparation and uses thereof
JP5690461B2 (ja) * 2002-11-15 2015-03-25 ヘルシン ヘルスケア ソシエテ アノニム 化学療法誘導嘔吐を治療するためのパロノセトロン
JO2735B1 (en) 2003-01-30 2013-09-15 هيلسين هيلث كير أس ايه. Liquid pharmaceutical formulations of palonosetron
US8598219B2 (en) 2003-01-30 2013-12-03 Helsinn Healthcare Sa Liquid pharmaceutical formulations of palonosetron
TWI355936B (en) 2003-02-18 2012-01-11 Helsinn Healthcare Sa Uses of palonosetron hydrochloride
US7060841B2 (en) 2003-06-03 2006-06-13 Chemagis Ltd. Process for preparing 1-methylindazole-3-carboxylic acid
DE602004010299T2 (de) 2003-12-22 2008-09-18 Memory Pharmaceuticals Corp. Indole, 1h-indazole, 1,2-benzisoxazole und 1,2-benzisothiazole und deren herstellung und anwendungen
US20060167072A1 (en) * 2004-01-30 2006-07-27 Helsinn Healthcare Sa Liquid pharmaceutical formulations of palonosetron
RU2417225C2 (ru) 2004-03-25 2011-04-27 Мемори Фармасьютиклз Корпорейшн Индазолы, бензотиазолы, бензоизотиазолы, бензизоксазолы и их получение и применение
JP2007534692A (ja) 2004-04-22 2007-11-29 メモリー・ファーマシューティカルズ・コーポレイション インドール、１ｈ−インダゾール、１，２−ベンズイソキサゾール、１，２−ベンゾイソチアゾール、ならびにその調製および使用
JP2007538011A (ja) 2004-05-07 2007-12-27 メモリー・ファーマシューティカルズ・コーポレイション １ｈ−インダゾール、ベンゾチアゾール、１，２−ベンゾイソキサゾール、１，２−ベンゾイソチアゾール、およびクロモン、ならびにそれらの調製および使用
BRPI0517494A (pt) * 2004-12-22 2008-10-14 Memory Pharm Corp composto, composição farmacêutica, método de ativação/estimulação seletiva de receptores nicotìnicos de a-7 em um paciente em que tal ativação/estimulação tem um efeito terapêutico, método de tratamento de um paciente que sofre de uma doença psicótica, uma doença neurodegenerativa que envolve uma disfunção do sistema colinérgico, e/ou uma condição de debilitação da memória e/ou da cognição, método de tratamento de um paciente que sofre de demência e/ou uma outra condição com perda da memória, método de tratamento de um paciente que sofre de debilitação da memória devido à debilitação cognitiva suave devido ao envelhecimento, mal de alzheimer, esquizofrenia, mal de parkinson, mal de huntington, mal de pick, mal de creutzfeldt-jakob, depressão, envelhecimento, trauma na cabeça, acidente vascular cerebral, hipoxia do snc, senilidade cerebral, demência de multiinfarto, hiv e/ou doença cardiovascular, método de tratamento e/ou prevenção da demência em um paciente com o mal de alzheimer, método de tratamento de um paciente para cortar o vìcio do álcool ou o tratamento de um paciente com a terapia anti-intoxicação, método de tratamento de um paciente para propiciar neuroproteção contra os danos associados com acidentes vasculares cerebrais e isquemia e excitotoxicidade induzida por glutamatos, método de tratamento de um paciente que sofre do vìcio da nicotina, dor, tontura do fuso horário, obesidade e/ou diabetes, método de indução do ato de parar fumar em um paciente, método de tratamento de um paciente que sofre de debilitação cognitiva suave (mci), demência vascular (vad), declìnio cognitivo associado com a idade (aacd), amnésia associada com a cirurgia com o coração aberto, parada cardìaca, anestesia geral, deficiências da memória devido à exposição a agentes anestésicos, debilitação cognitiva induzida pela privação do sono, sìndrome de fadiga crÈnica, narcolepsia, demência relacionada com a aids, debilitação cognitiva relacionada com a epilepsia, sìndrome de down, demência relacionada ao alcoolismo, debilitações da memória induzidas por drogas/substáncias, demência pugilìstica (sìndrome do boxeador), ou demência animal, método para o tratamento da perda da memória, método para o tratamento de um paciente que sofre de debilitação da memória, método para o tratamento ou a profilaxia de uma doença ou de uma condição resultante da disfunção da transmissão do receptor nicotìnico de acetilcolina em um paciente, método para o tratamento ou a profilaxia de uma doença ou de uma condição resultante de receptores nicotìnicos de acetilcolina defeituosos ou funcionando mal em um paciente, método para o tratamento ou a profilaxia de uma doença ou de uma condição resultante da transmissão suprimida do receptor nicotìnico de acetilcolina em um paciente, método para o tratamento ou a profilaxia de uma doença ou de uma condição resultante da perda de sinapses colinérgicas em um paciente, método para a proteção dos neurÈnios em um paciente com neurotoxicidade induzi
KR20070091665A (ko) * 2004-12-22 2007-09-11 세라밴스 인코포레이티드 인다졸－카르복사미드 화합물
US7868016B2 (en) 2005-07-13 2011-01-11 Baxter International Inc. Pharmaceutical formulations of endo-N-(9-methyl-9-azabicyclo[3,3.1]non-3-yl)-1-methyl-1H-indazole-3-carboxamide hydrochloride
US8106066B2 (en) 2005-09-23 2012-01-31 Memory Pharmaceuticals Corporation Indazoles, benzothiazoles, benzoisothiazoles, benzisoxazoles, pyrazolopyridines, isothiazolopyridines, and preparation and uses thereof
US8911751B2 (en) 2005-10-11 2014-12-16 Yissum Research Development Company Of The Hebrew University Of Jerusalem Compositions for nasal delivery
WO2007054784A1 (fr) * 2005-11-10 2007-05-18 Orchid Chemicals & Pharmaceuticals Limited Procede ameliore de preparation de chlorhydrate de granisetron
WO2007088557A1 (fr) * 2006-02-01 2007-08-09 Natco Pharma Limited Procédé d'obtention de base cristaline de granisétron de haute pureté
US20080004260A1 (en) * 2006-06-29 2008-01-03 Transcept Pharmaceuticals, Inc. Compositions of 5-HT3 antagonists and dopamine D2 antagonists for treatment of dopamine-associated chronic conditions
CA2666512C (fr) * 2006-10-24 2014-05-27 Helsinn Healthcare S.A. Capsules molles comprenant du chlorhydrate de palonosetron ayant une stabilite et une biodisponibilite ameliorees
ITMI20062230A1 (it) * 2006-11-22 2008-05-23 Acraf Composto 2-alchil-indazolico procedimento per preparalo e composizione farmaceutica che lo comprende
US8304426B2 (en) 2007-06-13 2012-11-06 Inke, S.A. Polymorphic form of Granisetron base, methods for obtaining it and formulation containing it
US20100298397A1 (en) * 2009-05-19 2010-11-25 Singh Nikhilesh N Method of treatment of obsessive compulsive disorder with ondansetron
EP2253316B1 (fr) 2009-05-20 2013-08-14 INSERM (Institut National de la Santé et de la Recherche Médicale) Antagonistes du récepteur 5-HT3 de la sérotonine pour une utilisation dans le traitement ou la prévention d'une pathologie de l'oreille interne avec déficits vestibulaires
ES2664599T3 (es) 2009-05-20 2018-04-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Antagonistas del receptor 5-HT3 de serotonina para uso en el tratamiento de trastornos vestibulares lesionales
JOP20130213B1 (ar) * 2012-07-17 2021-08-17 Takeda Pharmaceuticals Co معارضات لمستقبلht3-5
CN106795172B (zh) 2014-09-29 2020-07-28 武田药品工业株式会社 1-(1-甲基-1h-吡唑-4-基)-n-((1r,5s,7s)-9-甲基-3-氧杂-9-氮杂双环[3.3.1]壬-7-基)-1h-吲哚-3-甲酰胺的晶型
GB201511382D0 (en) 2015-06-29 2015-08-12 Imp Innovations Ltd Novel compounds and their use in therapy
WO2017044693A1 (fr) 2015-09-11 2017-03-16 Chase Pharmaceuticals Corporation Combinaison muscarinique et son utilisation pour lutter contre des troubles hypocholinergiques du système nerveux central
ES3065670T3 (en) 2017-04-24 2026-05-07 Alto Neuroscience Inc Compositions and method for treating depression
WO2024052684A1 (fr) 2022-09-09 2024-03-14 MyricX Pharma Limited Conjugué anticorps-médicament comprenant un inhibiteur de nmt et son utilisation

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2100909A1 (fr) * 1970-07-15 1972-03-24 Egyt Gyogyszervegyeszeti Gyar Amides de l'acide indazole-3-carboxylique et procedes de preparation
GB2100259B (en) * 1981-06-13 1984-10-31 Merrell Toraude & Co Treatment of migraine with tropyl benzoate derivatives
FR2531083B1 (fr) * 1982-06-29 1986-11-28 Sandoz Sa Nouveaux derives de la piperidine, leur preparation et leur utilisation comme medicaments
FR2548666A1 (fr) * 1983-07-08 1985-01-11 Delalande Sa Nouveaux derives du nor-tropane et du granatane, leur procede de preparation et leur application en therapeutique
DE3429830A1 (de) * 1983-08-26 1985-03-07 Sandoz-Patent-GmbH, 7850 Lörrach Automatische carbonsaeure- und sulfonsaeureester oder -amide
GB8525913D0 (en) * 1985-10-21 1985-11-27 Beecham Group Plc Compounds
DE3650772T2 (de) * 1985-04-27 2003-04-03 F. Hoffmann-La Roche Ag, Basel Derivate von Indazole-3-carboxamide und -3-carboxylsäure
US4937247A (en) * 1985-04-27 1990-06-26 Beecham Group P.L.C. 1-acyl indazoles
GB8510752D0 (en) * 1985-04-27 1985-06-05 Beecham Group Plc Compounds
GB8520616D0 (en) * 1985-08-16 1985-09-25 Beecham Group Plc Compounds

Also Published As

Publication number Publication date
CA1296004C (fr) 1992-02-18
AU594670B2 (en) 1990-03-15
US5034398A (en) 1991-07-23
JPH05194508A (ja) 1993-08-03
JP2696457B2 (ja) 1998-01-14
DK191186D0 (da) 1986-04-24
IE58313B1 (en) 1993-09-08
GR861103B (en) 1986-08-11
DE3687080T2 (de) 1993-03-25
AU5657986A (en) 1986-11-06
BG61324B2 (bg) 1997-05-30
EP0200444B1 (fr) 1992-11-11
US4886808A (en) 1989-12-12
CY1721A (en) 1994-05-06
DE3687080D1 (de) 1992-12-17
EP0200444A2 (fr) 1986-11-05
EP0200444A3 (en) 1988-12-14
ES8707948A1 (es) 1987-09-01
NZ215945A (en) 1990-04-26
IE861099L (en) 1986-10-27
DK191186A (da) 1986-10-28
ES554405A0 (es) 1987-09-01
DE3650772T2 (de) 2003-04-03
CS332391A3 (en) 1992-06-17
CZ286325B6 (cs) 2000-03-15
EP0498466A1 (fr) 1992-08-12
DE3650772D1 (de) 2002-08-29
HK66993A (en) 1993-07-16
PT82463A (en) 1986-05-01
DK170166B1 (da) 1995-06-06
PT82463B (pt) 1988-10-14
EP0498466B1 (fr) 2002-07-24

Similar Documents

Publication Publication Date Title
CY1721A (en) Azabicyclononyl-indazole-carboxamide having 5-ht antagonist activity
GB2174934B (en) Toolholder
EP0220401A3 (en) Underreamer
GB8601932D0 (en) Cutterhead
GB8618679D0 (en) Construction
GB8601636D0 (en) Toolholder
GB2192001B (en) Melatonin antagonist
GB2193091B (en) Compounds having calcium-regulatory activity
GB2180870B (en) Semi-submersible construction
GB8601151D0 (en) Dopings
EG17738A (en) Vasobrisin antagonists
GB8527884D0 (en) Sanitary arrangement
EP0204374A3 (en) Tripeptidic compounds having hypotensive activity
GB2182874B (en) Reamer
ZA865426B (en) Antihypertensive agents
GB2176997B (en) Cushion
GB8505562D0 (en) Cushion
ZA863645B (en) Yield-promoting agents
GB8610556D0 (en) Construction elements
GB8618196D0 (en) Antihypertensive agents
GB8509692D0 (en) Rest
GB8525013D0 (en) Antidiarrhoel agents
GR861916B (en) Antihypertensive agents
DE3664422D1 (en) Machine-tool structure
CA54598S (en) Bowl